Synthetic Biologics Appoints VP Corporate Development
Synthetic Biologics Inc. has appointed Dr Isaac J. Bright vice president of corporate development. Bright brings over 15 years of transactional and operational experience to the clinical stage company, which focuses on developing therapeutics to protect the gut microbiome. Prior to joining Synthetic Biologics, Bright was a partner at US private equity investment practice Merieux Development, before which he was vice president, corporate development and diagnostics at QuantaLife Inc.
You may also be interested in...
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Executives On The Move: CEOs Named At Evolve Biologics, Miragen Therapeutics, Receptor Life Sciences
Chief commercial officer appointed at Moderna.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.